Overview
NICE is unable to make a recommendation on tislelizumab (Tevimbra) in combination for untreated advanced non-small-cell lung cancer in adults. This is because the company did not provide an evidence submission.
Last reviewed: 23 April 2025
Next review: We will review this decision if the company decides to make a submission.